VECTIVBIO HLDG AG's ticker is VECT and the CUSIP is H9060V101. A total of 22 filers reported holding VECTIVBIO HLDG AG in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q1 2023 | $315,304 | -1.7% | 37,051 | 0.0% | 0.23% | -9.9% |
| Q4 2022 | $320,862 | +44.5% | 37,051 | 0.0% | 0.25% | +180.0% |
| Q3 2022 | $222,000 | +11.0% | 37,051 | 0.0% | 0.09% | +26.8% |
| Q2 2022 | $200,000 | +14.3% | 37,051 | 0.0% | 0.07% | -2.7% |
| Q1 2022 | $175,000 | -3.8% | 37,051 | 0.0% | 0.07% | +55.3% |
| Q4 2021 | $182,000 | – | 37,051 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 5,255,484 | $44,724,170 | 11.87% |
| TCG Crossover Management, LLC | 3,113,600 | $26,496,736 | 5.16% |
| CAXTON CORP | 156,651 | $1,345,549 | 3.40% |
| VR Adviser, LLC | 1,866,000 | $15,879,660 | 3.10% |
| Novo Holdings A/S | 3,610,461 | $30,725,023 | 2.03% |
| Cormorant Asset Management, LP | 2,536,617 | $21,587 | 1.42% |
| Vivo Capital, LLC | 2,333,300 | $19,856,383 | 1.38% |
| Orbimed Advisors | 5,156,561 | $43,882,334 | 0.86% |
| Frazier Life Sciences Management, L.P. | 1,352,199 | $11,628,911 | 0.84% |
| Bpifrance SA | 2,806,217 | $23,880,907 | 0.61% |